Exelixis | EXEL - Ricavi Di Vendita

Prezzo Delle Azioni
41.27
Cambio Giornaliero
0.01 0.02%
Mensile
-6.23%
Annuale
11.66%
Q1 Previsione
40.03




I Saldi Cambiamento Data
Acadia Pharmaceuticals USD 284M 5.4M 2025-12
Agios Pharmaceuticals USD 19.97M 7.07M 2025-12
Akebia Therapeutics USD 57.62M 1.14M 2025-12
Amgen USD 9.9B 340M 2025-12
AstraZeneca USD 15.5B 313M 2025-12
Bayer EUR 11.44B 1.78B 2025-12
BioMarin Pharmaceutical USD 875M 99M 2025-12
Bristol-Myers Squibb USD 12.5B 300M 2025-12
Cytokinetics USD 17.76M 15.83M 2025-12
Eisai JPY 219.94B 22.58B 2025-12
Eli Lilly USD 19.3B 1.7B 2025-12
Esperion Therapeutics USD 168.45M 81.14M 2025-12
Exelixis USD 598.66M 860K 2025-12
Genmab DKK 1.06B 36M 2025-12
Glaxosmithkline GBP 11.46B 59.16M 2025-12
Incyte USD 1.51B 140M 2025-12
Ionis Pharmaceuticals USD 203M 46M 2025-12
MacroGenics USD 41.23M 31.61M 2025-12
Merck USD 16.4B 880M 2025-12
Moderna USD 678M 342M 2025-12
Nektar Therapeutics USD 24.12M 635K 2024-09
Neurocrine Biosciences USD 805.5M 10.6M 2025-12
Novartis USD 13.86B 50M 2025-12
Pfizer USD 17.58B 880M 2025-12
Puma Biotechnology USD 80.54M 33.46M 2024-09
Sanofi EUR 12.2B 3.19B 2025-12
Takeda JPY 1.19T 80B 2025-12
Ultragenyx Pharmaceutical USD 207M 47M 2025-12
Xencor USD 28.24M 7.24M 2025-12